Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Jul 28, 2026--

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of a new video featuring actor and cancer advocate Patrick Dempsey that highlights the more than 55,000 Americans who will lose their lives to colorectal cancer (CRC) this year 1, a majority of which will not have been up to date with their colorectal cancer screening. 2

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728069431/en/

The video pays an emotional tribute to Americans from across the country who have passed from colorectal cancer in recent years, many of which have been pillars of their local communities and fierce colorectal cancer advocates themselves. In the film, Dempsey urges Americans to prioritize their CRC screenings with the new, innovative Shield™ blood test option by Guardant Health that make it quick and easy to screen for CRC.

Developed by the pioneers of oncology blood testing at Guardant Health with more than a million blood tests performed, Shield is the only FDA-approved blood test included in both the American Cancer Society (ACS) 3 and National Comprehensive Cancer Network (NCCN) guidelines.

“Seeing how many lives we’ve lost to colorectal cancer is heartbreaking, especially when it’s largely preventable through early, regular screening. Despite this, over 50 million Americans today continue to delay their lifesaving screenings. That’s why I chose to screen with Guardant’s Shield blood test that makes it quick and easy to complete your lifesaving cancer screening with just a blood draw,” said Patrick Dempsey. “If you’re 45 and over and at average risk for CRC, the most important step you can take for you and your loved ones is to get screened and not wait. Talk to your doctor about screening options including the Shield blood test that is making screening easier to complete.”

The burden of colorectal cancer in the U.S. is staggering and growing. According to data from ACS, colorectal cancer is the second leading cancer killer in the United States 4 and the number one cancer killer for adults under 50. 5

"Doug was a devoted husband, son, father, grandfather, and friend whose charm, wit and strength touched everyone around him,” said Tracy Compton of her husband Doug who is memorialized in the video and passed from colorectal cancer in 2025. “He found his greatest joy in his family—especially in the simple, meaningful moments shared over weekly dinners and annual vacations. So many people are afraid of being tested and finding out they have cancer, but colorectal cancer can be cured when caught early. His legacy is a reminder to cherish time with your loved ones and encourage those you love to prioritize their colorectal cancer screening."

“To me, Rose was not only my wife of more than 30 years, but my best friend and greatest source of strength since we were 5. She devoted her life to her family and helping others, always leading with kindness, wisdom, and perseverance,” said Eric Hausmann of his late wife. “Throughout her 12-year battle with colon cancer, she faced every challenge with remarkable courage and never stopped living life to the fullest. Oftentimes she would walk up to strangers and ask them if they had gotten screened. She wanted everyone to know this disease was beatable if caught early enough. Her story is a powerful reminder of why awareness, early detection and continued progress in colorectal cancer matters so deeply.”

"David was an accomplished engineer, singer, songwriter, and guitarist who — despite the odds — recorded an entire album of original music while bravely facing stage IV colorectal cancer,” shared Amy Duffy of her late husband David. “His creativity and determination never wavered, and neither did his love for the girls and me. I’m proud to see him continue to inspire people today and encourage more people to take charge of their health and get screened for colorectal cancer.”

In the real-world experience with approximately 200,000 patients tested, Shield is proven to increase screening rates with over 90% of patients completing the test 6 – a significant improvement in screening adherence rates over other types of tests.

For more information about the Shield blood test, visit ShieldBloodTest.com.

About Shield

Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

About The Dempsey Center

The Dempsey Center was founded by actor Patrick Dempsey in 2008 after his mother’s experience with cancer and as a way to give back to his hometown community of Lewiston, Maine. Today, the Dempsey Center has grown to two locations in Lewiston and Westbrook, Maine, a hospitality home in Portland, Maine, and has adapted to providing robust support virtually via Dempsey Connects. Our programs provide a wide range of comprehensive supportive cancer care that address the physical, functional, social, and emotional well-being of people impacted by cancer. All services are provided at no cost to cancer patients, survivors, care partners, family members, and friends. Learn more by visiting DempseyCenter.org.

Guardant Health Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

1 American Cancer Society. Fast Facts: Colorectal Cancer Statistics 2026. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/crc-2026/crc-2026-fast-facts.pdf
2 Doubeni, C, et al. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association with Risk of Death. Gastroenterology. 2019 Jan; 156(1): 63–74.e6.
3 American Cancer Society. American Cancer Society Updates Colorectal Cancer Screening Guideline: Major Changes Emphasize Blood-Based and At-Home Stool Testing. Published May 27, 2026. Accessed June 19, 2026. https://pressroom.cancer.org/colorectal-cancer-screening-guideline-update-2026
4 American Cancer Society. Colorectal Cancer Facts & Figures. Accessed June 19, 2026. https://www.cancer.org/research/cancer-facts-statistics/colorectal-cancer-facts-figures.html.
5 American Cancer Society. Mortality Under 50 Declines for 4 of 5 Leading Cancers in U.S., but Colorectal Now Top Cancer Killer, New ACS Study Finds. Published January 22, 2026. https://pressroom.cancer.org/under-50-mortality-declines.
6 Graham-Adderton, C., Guerra, C. E., Ngo-Metzger, Q., Hoang, T., & Raymond, V. M. (2025). Implementation of blood-based colorectal cancer screening: Real-world adherence and outcomes.

David Callan, 49, was an accomplished engineer, singer, songwriter, and guitarist who recorded an entire album of original music while bravely facing stage IV colorectal cancer

Rose Hausmann, 53, devoted her life to her family and helping others, always leading with kindness, wisdom, and perseverance

Doug Compton, 58, was a devoted husband, son, father, grandfather, and friend whose charm, wit and strength touched everyone around him

MIDLAND, Texas--(BUSINESS WIRE)--Jul 28, 2026--

AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, today announced that the launch of BlueBird 11, 12, and 13 satellites is currently scheduled for Wednesday, August 5, 2026, from Cape Canaveral Space Force Station, Florida, aboard a Falcon 9 rocket. Liftoff is targeted for 3:42 a.m. EDT with an additional opportunity available at 5:10 a.m.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728125090/en/

The mission follows the successful June 2026 launch of BlueBird satellites 8, 9, and 10, and with BlueBird satellites 14, 15, and 16 already preparing for the next mission, and production advancing through satellite 42, the company continues to execute against its plan to deploy its constellation at scale.

BlueBird satellites 11, 12, and 13 will further expand AST SpaceMobile's space-based cellular broadband network, supporting voice, data, and video services directly to standard, unmodified smartphones while also enabling a growing range of commercial and government applications.

The satellites incorporate AST SpaceMobile's next-generation stackable architecture and advanced lightweight composite carbon structures, enabling efficient multi-satellite launches and accelerating constellation deployment.

“The upcoming launch of BlueBirds 11, 12, and 13 showcases our ability to rapidly and consistently build, launch, and deploy the largest phased arrays in low Earth orbit,” said Scott Wisniewski, President of AST SpaceMobile. “This orbital launch, combined with expanded manufacturing capacity and the recent successful launch and deployment of BlueBird satellites 8, 9, and 10, position us for beta services later this year with our space-based cellular broadband coverage."

These next-generation BlueBird satellites are expected to deliver nearly double the peak download speeds achieved by the company's initial Block 1 BlueBird satellites, which recently demonstrated peak download speeds of 98.9 Mbps directly to standard smartphones. The mission represents another step toward expanding AST SpaceMobile's global direct-to-device broadband constellation and bringing cellular broadband connectivity to billions of people worldwide who remain unconnected or underconnected.

Designed and manufactured through AST SpaceMobile's highly vertically integrated operating model, with approximately 95% of the technology developed in-house, BlueBird satellites feature the world's largest commercial communications arrays deployed in low Earth orbit. Supported by a workforce of more than 2,250 employees across over 500,000 square feet of global manufacturing and operations facilities, AST SpaceMobile continues to expand its ability to manufacture and deploy its next-generation satellites at scale.

Members of the public and investors are encouraged to watch a live broadcast on the launch day from AST SpaceMobile's YouTube channel.

AST SpaceMobile has agreements with nearly 60 mobile network operators globally with over 3 billion subscribers combined and strategic partnerships with AT&T, Verizon, Vodafone, Rakuten, Google, Bell, Telus, stc Group and American Tower.

The exact timing of orbital launches is subject to change based on a number of factors, including launch readiness of the launch provider, weather conditions, and other factors, many of which are beyond our control.

About AST SpaceMobile

AST SpaceMobile is building the first and only global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on our extensive IP and patent portfolio, and designed for both commercial and government applications. Our engineers and space scientists are on a mission to enable 4G and 5G space-based cellular broadband to every device, everywhere, for today’s nearly 6 billion mobile subscribers globally. For more information, follow AST SpaceMobile on YouTube, X (Formerly Twitter), LinkedIn and Facebook. Watch this video for an overview of the SpaceMobile mission.

Forward-Looking Statements

This communication contains “forward-looking statements” that are not historical facts, and involve risks and uncertainties that could cause actual results of AST SpaceMobile to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “would,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside AST SpaceMobile’s control and are difficult to predict.

Factors that could cause such differences include, but are not limited to: (i) expectations regarding AST SpaceMobile’s strategies and future financial performance, including AST's future business plans or objectives, expected functionality of the SpaceMobile Service, anticipated timing of the launch of the Block 2 BlueBird satellites, anticipated demand and acceptance of mobile satellite services, prospective performance and commercial opportunities and competitors, the timing of obtaining regulatory approvals, ability to finance its research and development activities, commercial partnership acquisition and retention, products and services, pricing, marketing plans, operating expenses, market trends, revenues, liquidity, cash flows and uses of cash, capital expenditures, and AST SpaceMobile’s ability to invest in growth initiatives; (ii) the negotiation of definitive agreements with mobile network operators relating to the SpaceMobile Service that would supersede preliminary agreements and memoranda of understanding and the ability to enter into commercial agreements with other parties or government entities; (iii) the ability of AST SpaceMobile to grow and manage growth profitably and retain its key employees and AST SpaceMobile’s responses to actions of its competitors and its ability to effectively compete; (iv) changes in applicable laws or regulations; (v) the possibility that AST SpaceMobile may be adversely affected by other economic, business, and/or competitive factors; (vi) the outcome of any legal proceedings that may be instituted against AST SpaceMobile; and (vii) other risks and uncertainties indicated in the Company’s filings with the Securities and Exchange Commission (SEC), including those in the Risk Factors section of AST SpaceMobile’s Form 10-K filed with the SEC on March 2, 2026, its Form 10-Q for the fiscal quarter ended March 31, 2026 filed with the SEC on May 11, 2026 and the future reports that it may file from time to time with the SEC.

AST SpaceMobile cautions that the foregoing list of factors is not exclusive. AST SpaceMobile cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors in AST SpaceMobile’s Form 10-K filed with the SEC on March 2, 2026, its Form 10-Q for the fiscal quarter ended March 31, 2026 filed with the SEC on May 11, 2026 and the future reports that it may file from time to time with the SEC. AST SpaceMobile’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, AST SpaceMobile disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

AST SpaceMobile Announces Launch Date for BlueBird Satellites 11, 12, and 13